Highest-materiality recent filing
Cognition Therapeutics Q2 2026 net loss $3.9M; advances Phase 3 plan for DLB psychosis
Net loss of $3.9M ($0.04 per share) vs $6.7M loss in Q2 2025.
FDA agreed that DLB psychosis is an approvable outcome; key aspects of Phase 3 trial design aligned.
Aaron Fletcher, Ph.D. elected with 15,093,537 votes for, 680,677 withheld, 34,035,661 broker non-votes.
Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis
Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.
Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis
FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.
Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20
Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.
Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine
Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.
Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting
Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.
Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.
Cognition Therapeutics enters $75M ATM offering with Jefferies, terminates prior $40M ATM
Entered ATM sales agreement with Jefferies LLC for up to $75M of common stock (December 18, 2025).
Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.
Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress
Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.
Cognition Therapeutics raises ~$30.1M via registered direct offering of 14.7M shares at $2.05/share
Gross proceeds of $30.1M from sale of 14.7M shares at $2.05/share in a registered direct offering.
Cognition Therapeutics regains Nasdaq minimum bid price compliance
On Aug 26, 2025, Nasdaq confirmed Cognition Therapeutics regained compliance with the $1.00 minimum bid price rule.
Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones
Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.
Cognition Therapeutics shareholders elect two directors, ratify EY as auditor for 2025
Peggy Wallace re-elected as Class I director with 8,566,458 for, 2,590,981 withheld.
Cognition Therapeutics launches expanded access program for zervimesine in DLB
Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.
Cognition Therapeutics files investor presentation on pathogenic oligomers approach
Filed investor presentation dated June 2025 under Item 8.01.
Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial
Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.
Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's
Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.
Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.
Cognition Therapeutics gets Nasdaq extension to Sept 8, 2025; transfer to Capital Market
Received Nasdaq extension notice on March 12, 2025, granting 180 additional days until Sept 8, 2025 to regain $1.00 minimum bid price.
Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy
Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.
Cognition Therapeutics files corporate presentation; no material new data disclosed
Company furnished a corporate presentation discussing its focus on targeting pathogenic oligomers for neurodegenerative diseases.
Cognition Therapeutics files investor presentation with no material updates disclosed
Filed an investor presentation under Item 7.01 for Regulation FD purposes.
Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study
Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.
Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group
Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.
Cognition Therapeutics furnishes investor presentation on amyloid beta oligomer approach
Presentation titled 'Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of CNS Disorders' dated September 2024 made available.
Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Deficiency letter received on September 12, 2024; stock continues trading under CGTX.
Cognition Therapeutics furnishes investor presentation with no new material facts disclosed
Filed an investor presentation under Item 7.01 on August 28, 2024.
Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data
Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.
Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.
Stockholders elect Khattar and Monia as Class III directors at AGM
Jack A. Khattar elected with 13,573,718 votes for, 2,573,793 withheld, 8,421,943 broker non-votes.
Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024
Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.
Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025
Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.
Cognition Therapeutics raises ~$10.4M in public offering of 6.57M shares at $1.75
Issued 6,571,428 shares of common stock at $1.75 per share; net proceeds ~$10.4M after expenses.
Cognition Therapeutics reports preliminary FY2023 net loss of $25.6M; cash at $29.9M
Preliminary net loss for FY2023 expected to be approximately $25.6 million.
Cognition Therapeutics grants performance stock units to CEO, CFO, and CMO
CEO Lisa Ricciardi awarded 150,000 PSUs vesting on clinical milestone achievement.
Cognition Therapeutics posts January 2024 investor presentation
Presentation filed as Exhibit 99.1; covers disease-modifying medicines for neurodegenerative disorders.
Cognition Therapeutics reports Q3 net loss of $6.7M; updates on Alzheimer’s and DLB trials
Net loss of $6.7M ($0.22 per share) in Q3 2023 vs $6.6M ($0.29 per share) in Q3 2022.
Cognition Therapeutics provides pipeline update; SHINE interim shows 3-point ADAS-Cog benefit
Cash and equivalents $37.2M as of June 30, 2023; expected runway through Q3 2024.
Cognition Therapeutics files investor presentation; no material news disclosed
Presentation covers general pipeline and Phase 3 preparation; no specific financial or clinical data.
Cognition Therapeutics Q2 net loss $4.7M; positive SEQUEL topline for CT1812
Net loss of $4.7M ($0.16/sh) vs $5.8M ($0.25/sh) in Q2 2022; R&D expense $8.5M.
Cognition Therapeutics announces positive Phase 2 SEQUEL topline results for CT1812 in Alzheimer's
Phase 2 SEQUEL study met primary safety and tolerability endpoints; CT1812 well-tolerated with no treatment-related SAEs.
Cognition Therapeutics reports 2023 annual meeting vote results
Annual Meeting held June 9, 2023; virtual format.
Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials
Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.
Cognition Therapeutics appoints John Doyle as CFO effective May 1, 2023
John Doyle appointed CFO effective May 1; succeeds interim CFO Andrew Einhorn, who serves until May 15.
Filing under Item 7.01 attaches a presentation for an analyst breakfast meeting in April 2023.
Meta-analysis of 24 participants (SHINE-A) and full SPARC dataset showed CT1812 significantly alters 28 biomarkers.
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
Completed enrollment in Phase 2 SEQUEL trial of CT1812 for mild-to-moderate Alzheimer's disease; topline results expected later 2023.
Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.
On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.
the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.
the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022
On October 29, 2021, Mark H. Breedlove notified the Board that he intends to resign as a member of the Board, effective December 31, 2021.
Effective November 1, 2021, in connection with the Board Increase, the Board appointed Ellen B. Richstone to serve as a Class I member of the Board
Max materiality 0.90 · Median 0.57 · Most common event other_material